Feasibility, toxicity, and biologic response of interleukin-2 after consolidation chemotherapy for acute myelogenous leukemia: A report from the Children's Cancer Group

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 914-919

  Sievers, Eric L ^a   Lange, Beverly J ^a   Sondel, Paul M ^a   Krailo, Mark D ^a   Gan, Jacek ^a   Liu Mares, Wen ^a   Feig, Stephen A ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD56 ANTIGEN; INTERLEUKIN 2 RECEPTOR; RECOMBINANT INTERLEUKIN 2;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ALPHA CHAIN; ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CAPILLARY LEAK SYNDROME; CHILD; CLINICAL ARTICLE; DRUG EFFICACY; DRUG TOLERABILITY; ELECTROLYTE DISTURBANCE; FEMALE; FEVER; HUMAN; HYPERGLYCEMIA; HYPOTENSION; INFANT; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA REMISSION; LYMPHOCYTE COUNT; MALE; PRIORITY JOURNAL; RASH; SEPTICEMIA; TACHYCARDIA; THROMBOCYTOPENIA;

EID: 0031884911     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.914     Document Type: Article

References (30)

1. Woods WG, Kobrinsky N, Buckley JD, et al: Timed-sequential induction therapy improves postremission outcome in acute myeloid leukemia: A report from the Children's Cancer Group. Blood 87:4979-4989, 1996
2. Horowitz MM, Gale RP, Sondel PM, et al: Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75:555-562, 1990
3. Foa R, Meloni G, Tosti S, et al: Treatment of acute myeloid leukaemia patients with recombinant interleukin-2: A pilot study. Br J Haematol 77:491-496, 1991
4. Maraninchi D, Blaise D, Viens P, et al: High-dose recombinant interleukin-2 and acute myeloid leukemias in relapse. Blood 78:2182-2187, 1991
5. Meloni G, Foa R, Vignetti M, et al: Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia. Blood 84:2158-2163, 1994
6. Meloni G, Vignetti M, Andrizzi C, et al: Interleukin-2 for the treatment of advanced acute myelogenous leukemia patients with limited disease: Updated experience with 20 cases. Leuk Lymph 21:429-435, 1996
7. Massumoto C, Benyunes MC, Sale G, et al: Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy. Bone Marrow Transplant 17:351-356, 1996
8. Benyunes MC, Massumoto C, York A, et al: Interleukin-2 with or without lymphokine-activated killer cells as consolidate immunotherapy after autologous bone marrow transplantation for acute myelogenous leukemia. Bone Marrow Transplant 12:159-163, 1993
9. Soiffer RJ, Murray C, Gonin R, et al: Effect of low-dose interleukin-2 on disease relapse after T-cell - depleted allogeneic bone marrow transplantation. Blood 84:964-971, 1994
10. Brune M, Hellstrand K: Remission maintenance therapy with histamine and interleukin-2 in acute myelogenous leukaemia. Br J Haematol 92:620-626, 1996
11. Robinson N, Benyunes MC, Thompson JA, et al: Interleukin-2 after autologous stem-cell transplantation for hematologic malignancy: A phase I/II study. Bone Marrow Transplant 19:435-442, 1997
12. Wells RJ, Woods WG, Lampkin BC, et al: Impact of high-dose cytarabine and asparaginase intensification on childhood acute myeloid leukemia: A report from the Childrens Cancer Group. J Clin Oncol 11:538-545, 1993
13. Oken MM, Creech RH, Tormey DC, et al: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5:649-655, 1982
14. Voss SD, Hank JA, Nobis CA, et al: Serum levels of the low-affinity interleukin-2 receptor molecule (TAC) during IL-2 therapy reflect systemic lymphoid mass activation. Cancer Immunol Immunother 29:261-269, 1989
15. Lehmann EL: Statistical Methods Based on Ranks, Nonparametrics. San Francisco, CA, Holden-Day, 1975
16. Vial T, Descotes J: Immune-mediated side-effects of cytokines in humans. Toxicology 105:31-57, 1995
17. Parrado A, Rodriguez-Fernandez JM, Casares S, et al: Generation of LAK cells in vitro in patients with acute leukemia. Leukemia 7:1344-1348, 1993
18. Slavin S, Or R, Kapelushnik Y, et al: Immunotherapy of minimal residual disease in conjunction with autologous and allogeneic bone marrow transplantation (BMT). Leukemia 6:164-166, 1992 (suppl 4)
19. Bergmann L, Heil G, Kolbe K, et al: Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myeloblastic leukemia. Leuk Lymph 16:271-279, 1995
20. Toren A, Ackerstein A, Slavin S, et al: Role of interleukin-2 in human hematological malignancies. Med Oncol 12:177-186, 1995
21. Wiernik PH, Dutcher JP, Todd M, et al: Polyethylene glycolated interleukin-2 as maintenance therapy for acute myelogenous leukemia in second remission. Am J Hematol 47:41-44, 1994
22. Wexler LH, Sondel PM, Casper J: Use of biological response modifiers and biologic therapy in pediatric oncology, in Pochedly C (ed): Neoplastic Diseases of Childhood, Toronto, Canada, Harwood, 1995, pp 63-86
23. Rosenberg SA, Yang JC, Topalian SL, et al: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J Am Med Assoc 271:907-913, 1994
24. Fisch P, Oettel K, Fudim N, et al: MHC-unrestricted cytotoxic and proliferative responses of two distinct human gamma/delta T cell subsets to Daudi cells. J Immunol 148:2315-2323, 1992
25. Sondel PM, Kohler PC, Hank JA, et al: Clinical and immunological effects of recombinant interleukin-2 given by repetitive weekly cycles to patients with cancer. Cancer Res 48:2561-2567, 1988
26. Sosman JA, Kohler PC, Hank JA, et al: Repetitive weekly cycles of interleukin-2. II. Clinical and immunologic effects of dose, schedule, and addition of indomethacin. J Natl Cancer Inst 80:1451-1461, 1988
27. Voss SD, Hong R, Sondel PM: Severe combined immunodeficiency, interleukin-2 (IL-2), and the IL-2 receptor: Experiments of nature continue to point the way. Blood 83:626-635, 1994
28. Stasi R, Zinzani PL, Galieni P, et al: Detection of soluble interleukin-2 receptor and interleukin-10 in the serum of patients with aggressive non-Hodgkin's lymphoma. Identification of a subset at high risk of treatment failure. Cancer 74:1792-1800, 1994
29. Ambrosetti A, Nadali G, Vinante F, et al: Serum levels of soluble interleukin-2 receptor in Hodgkin disease. Relationship with clinical stage, tumor burden, and treatment outcome. Cancer 72:201-206, 1993
30. Bogner MP, Voss SD, Bechhofer R, et al: Serum CD25 levels during interleukin-2 therapy: Dose dependence and correlations with clinical toxicity and lymphocyte surface sCD25 expression. J Immunother 11:111-118, 1992